Advertisement


Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Opportunities to Optimize Cancer Policies Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement



Nov
28
Today In Oncology
Effect of Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Patients Aged 70 and Older Receiving Treatment for Advanced Cancer
5-Year Outcomes With Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma
5-Year Survival and Cure Fraction Estimates for Childhood Cancer in Europe From 2000 to 2014 EUROCARE-6
ALND vs Axillary Radiotherapy in Sentinel Node–Positive Breast Cancer
UICC Outlines Antimicrobial Resistance in Cancer Treatment
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside